Anti-Vascular Endothelial Growth Factor Therapeutics Market to Grow at 0.9% CAGR Through 2032: Persistence Market Research

The global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market is poised for modest but steady expansion over the next decade, driven by an aging population and the growing prevalence of eye-related and cancerous conditions. According to the latest insights from Persistence Market Research, global sales of Anti-VEGF therapeutics reached US$ 11.9 billion in 2021. The market is projected to grow at a CAGR of 0.9% between 2022 and 2032, reaching US$ 13.1 billion by the end of the forecast period.

The leading product in the market, Eylea, has continued to capture the highest revenue share due to its efficacy in treating multiple retinal disorders. North America stands out as the top geographical segment, commanding more than 40% market share in 2021. This dominance is attributed to increased healthcare spending, regulatory approvals, and the region's large geriatric population. Age-Related Macular Degeneration (AMD) remains the most prevalent condition treated using Anti-VEGF therapeutics, making it a key driver behind sustained market demand.

✅Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/33243

✅Key Highlights from the Report:

➤ The market is projected to grow from US$ 12 Bn in 2022 to US$ 13.1 Bn by 2032
➤ Eylea remains the leading revenue-generating product in the market
➤ North America held the largest regional share at over 40% in 2021
➤ The U.S. market alone is expected to reach US$ 4.6 Bn by 2032
➤ Bevacizumab and Ranibizumab are among the most widely used Anti-VEGF drugs
➤ Japan is forecasted to see the fastest CAGR at 1.2% through 2032

✅Market Segmentation

The Anti-VEGF Therapeutics Market can be segmented by product type, where monoclonal antibodies, tyrosine kinase inhibitors, and soluble VEGFR hybrids are key categories. Among these, monoclonal antibodies such as Bevacizumab and Ranibizumab dominate, largely due to their proven efficacy and broad regulatory approval. Eylea (aflibercept), a fusion protein acting as a decoy receptor for VEGF, has particularly gained traction due to its extended dosing schedule and strong clinical performance.

From an end-user perspective, the market is primarily driven by hospital pharmacies, retail pharmacies, and online pharmacies. Hospitals remain the largest consumers due to the complex administration procedures often associated with these biologics. Meanwhile, the growth of online pharmacies-fueled by increased telemedicine adoption-is emerging as a secondary growth lever, particularly in developed countries where patient convenience and access to care are evolving rapidly.

✅Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/anti-vascular-endothelial-growth-factor-therapeutics-market.asp

✅Regional Insights

In North America, a combination of high healthcare expenditure, favorable reimbursement policies, and strong presence of key players has kept the region at the forefront of the Anti-VEGF therapeutics market. The U.S. continues to be a dominant market, backed by rising diabetic retinopathy cases and high adoption rates of biologics.

Meanwhile, Asia Pacific-with Japan leading the growth-is seeing rising opportunities due to an expanding elderly population and improving healthcare infrastructure. The region also benefits from growing awareness about retinal diseases and increasing diagnostic rates, particularly in urban areas.

✅Market Drivers

The Anti-VEGF therapeutics market is driven primarily by the increasing prevalence of retinal disorders such as AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). As the global population ages, the incidence of these diseases rises significantly, with Anti-VEGF therapies offering the most effective clinical solution. According to WHO, over 196 million people are affected by AMD globally, providing a strong demand foundation for these therapies.

Additionally, the role of angiogenesis in cancer has led to the application of Anti-VEGF agents in oncology. With the global burden of cancer expected to grow by over 70% in the next two decades, anti-angiogenic treatments are gaining traction as a complementary strategy in cancer therapeutics. This dual application across ophthalmology and oncology boosts the overall market potential.

✅Market Restraints

Despite its strengths, the Anti-VEGF therapeutics market faces some key restraints. Angiogenesis is not always the primary cause of tumor progression, which limits the effectiveness of VEGF-targeted therapy in certain cancer types. Moreover, the need for repeated intraocular injections, often monthly or bi-monthly, is burdensome for both patients and caregivers, which affects compliance and overall treatment outcomes.

In addition, limited access to screening and diagnostics in developing regions continues to restrict market penetration. In these areas, conditions like diabetic retinopathy often go undiagnosed until they reach advanced stages, by which time treatment options are limited and outcomes less favorable.

✅Market Opportunities

Opportunities in the market are largely driven by advancements in drug delivery systems. Long-acting formulations and sustained-release implants like the Port Delivery System (PDS) developed by Roche aim to reduce injection frequency, significantly improving patient adherence and quality of life.

Moreover, the expansion into emerging markets like India, Brazil, and Southeast Asia offers significant room for growth. These regions are experiencing a surge in chronic diseases such as diabetes and hypertension, which are precursors to many retinal conditions treatable by Anti-VEGF agents.

✅Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/33243

✅Reasons to Buy the Report:

✔ In-depth analysis of current and future market trends and opportunities
✔ Comprehensive segmentation covering product types, end-users, and regions
✔ Competitive insights including profiles of key market players and recent developments
✔ Detailed market projections and growth analysis through 2032
✔ Strategic recommendations to capitalize on untapped market potential

✅Company Insights

✦ F. Hoffmann-La Roche Ltd.
✦ Biogen
✦ Pfizer Inc.
✦ Coherus BioSciences
✦ Amgen Inc.
✦ Regeneron Pharmaceuticals Inc.
✦ Bayer AG
✦ Novartis AG

Recent Developments:

✦ In May 2020, F. Hoffmann-La Roche Ltd. announced top-line Phase III trial results for a ranibizumab formulation using the Port Delivery System, showing promise for reducing treatment burden in patients.
✦ In May 2019, Regeneron Pharmaceuticals received FDA approval for expanding Eylea use to treat all stages of diabetic retinopathy, significantly broadening its market potential.

✅Conclusion

The Anti-Vascular Endothelial Growth Factor Therapeutics Market is witnessing gradual yet consistent growth, largely influenced by demographic trends, chronic disease prevalence, and innovations in drug development. With a modest CAGR of 0.9%, the market may not be among the fastest growing in the pharmaceutical sector, but its long-term potential remains promising due to its relevance in both ophthalmology and oncology.

As technologies like long-acting delivery systems mature and expand access to treatment in emerging regions improves, the market is expected to unlock new growth frontiers. Stakeholders-from manufacturers to healthcare providers-must focus on reducing the treatment burden and ensuring wider availability of diagnostic and therapeutic solutions. Backed by strong fundamentals and consistent research insights from organizations like Persistence Market Research, the Anti-VEGF market is set to maintain its critical role in improving patient outcomes worldwide.

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.